WAM
AXSM icon

Wolverine Asset Management’s Axsome Therapeutics AXSM Stock Holding History

Wolverine Asset Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-10,242
Closed -$579K – 2163
2021
Q1 		$579K Sell
10,242
-1,121
-10% -$78.9K ﹤0.01% 857
2020
Q4 		$925K Buy
+11,363
New +$850K 0.01% 669
2020
Q3 		– Sell
-7,125
Closed -$586K – 1563
2020
Q2 		$586K Buy
7,125
+3,902
+121% +$300K 0.01% 685
2020
Q1 		$189K Buy
+3,223
New +$263K ﹤0.01% 903

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Wolverine Asset Management's AXSM Position: Q2 2021 in Review

Wolverine Asset Management sold out of Axsome Therapeutics (AXSM) in Q2 2021, closing a stake of 10,242 shares — an estimated $579K sold.

Wolverine Asset Management first reported a position in AXSM in Q1 2020 and held it in 4 quarters. The position peaked at $925K in Q4 2020. 176 funds tracked by Wall St. Rank hold AXSM as of Q2 2021.

  • Wolverine Asset Management reported no remaining Axsome Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Wolverine Asset Management sold 10,242 Axsome Therapeutics shares in Q2 2021, an estimated $579K.
  • Wolverine Asset Management first reported a position in Axsome Therapeutics in Q1 2020 and held it in 4 quarters.
  • Wolverine Asset Management's Axsome Therapeutics position peaked at $925K in Q4 2020.
  • 176 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2021.

Based on Wolverine Asset Management's 13F filing for Q2 2021, filed 13 Aug 2021.